Cytomel (Liothyronine) Pre-Surgery Hold Window

Why the Pre-Surgery Hold Matters for Liothyronine

Liothyronine is the synthetic form of triiodothyronine (T3), the most biologically active thyroid hormone. Unlike levothyroxine (T4), which is a pro-hormone requiring peripheral deiodination to become active, T3 binds nuclear thyroid hormone receptors directly and with roughly four times the potency of T4 [1]. That potency is the core of the perioperative problem.

Under general anesthesia, the cardiovascular system is already stressed. Elevated circulating T3 amplifies myocardial oxygen demand, increases heart rate, and sensitizes the myocardium to catecholamines. Surgical manipulation, intubation, and the catecholamine surge that accompanies laryngoscopy can then trigger tachyarrhythmias or hemodynamic instability in a patient whose T3 levels are supraphysiologic or even high-normal [2].

The Pharmacokinetic Case for a 7 to 10 Day Hold

T3's plasma half-life is approximately 19 to 24 hours in euthyroid adults [3]. That short half-life cuts both ways. It means levels fall fast after the last dose, so a 7-day hold eliminates roughly 99% of steady-state circulating T3. It also means levels rise fast after a missed dose restart. The 7-to-10-day window is not arbitrary. At 7 half-lives, a drug is below 1% of its steady-state concentration. For a drug with a 1-day half-life, 7 days achieves that clearance mathematically.

Standard-dose liothyronine (typically 25 to 75 mcg daily) reaches full steady state within 3 to 5 days of initiation or dose change [4]. A patient who has been on a stable dose for weeks carries a predictable tissue burden. Stopping 7 days out gives both plasma and tissue T3 levels time to normalize before anesthetic induction.

Cardiac Sensitization Under Anesthesia

Volatile anesthetic agents such as sevoflurane and isoflurane independently reduce systemic vascular resistance and myocardial contractility. In a patient with even mildly elevated T3, the compensatory tachycardia that normally offsets reduced contractility becomes exaggerated. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that overt hyperthyroidism increases perioperative cardiac complication rates, and subclinical T3 excess carries a qualitatively similar, if smaller, risk [5].

Succinylcholine, ketamine, and many vasopressors used intraoperatively act partly through catecholamine pathways. Because T3 upregulates beta-adrenergic receptor density on cardiomyocytes, the same dose of epinephrine or phenylephrine produces a larger hemodynamic response in a patient with elevated T3 than in a euthyroid patient [6].

T3 vs. T4: Why Levothyroxine Does Not Carry the Same Perioperative Risk

Patients on combination T4 plus T3 therapy (as studied by Bunevicius et al. In their landmark 1999 NEJM trial) often ask whether they need to hold both medications. The short answer is no. Levothyroxine can typically be continued through surgery, or held only on the morning of surgery if strict nil-per-os (NPO) rules apply, with no meaningful clinical consequence.

The Half-Life Difference Is Decisive

Levothyroxine has a plasma half-life of 6 to 7 days [7]. Holding a single morning dose on surgery day changes steady-state T4 levels by well under 10%. Even holding T4 for a full week drops circulating levels by only about 50%. Because T4 itself has weak receptor affinity compared to T3, that modest drop rarely produces clinical hypothyroidism during the short perioperative window.

T3, by contrast, drops to near-undetectable levels within 5 to 7 days of the last dose. That rapid clearance is exactly what makes the 7-to-10-day hold both feasible and effective.

Bunevicius 1999 and the Clinical Context for Combination Therapy

In the Bunevicius et al. NEJM 1999 trial (N=33), substituting 12.5 mcg of T3 for 50 mcg of T4 in patients already taking levothyroxine produced measurable improvements in mood and cognitive performance while maintaining similar TSH control [8]. That trial popularized T4/T3 combination prescribing, which means a growing number of patients presenting for surgery are on both agents. Clinicians managing these patients perioperatively must recognize that the T3 component, not the T4 component, drives the hold requirement.

Bunevicius and colleagues did not study perioperative outcomes, but the pharmacodynamic data their work generated, specifically around T3's receptor-level potency, directly informs why T3 must be held while T4 can be continued.

Specific Hold Protocol: Step-by-Step Guidance

Step 1: Confirm the Indication and Current Dose

Before modifying any thyroid regimen, confirm why the patient is on liothyronine. Indications include:

• Primary hypothyroidism not adequately controlled on levothyroxine alone
• Combination T4/T3 therapy for mood or cognitive complaints (Bunevicius rationale)
• Thyroid hormone suppression therapy in differentiated thyroid cancer (DTC) survivors
• Short-term use during radioactive iodine (RAI) preparation

Each indication carries a different risk calculation. A DTC patient on suppressive liothyronine may have a TSH target below 0.1 mU/L. Holding T3 for 10 days will allow TSH to rise, which is acceptable for a short elective surgery window but requires a documented plan to restart promptly.

Step 2: Set the Hold Start Date

For most elective surgeries, count back 7 to 10 days from the procedure date and mark that as the last liothyronine dose day. For urgent or semi-urgent surgeries where a full hold is not possible, alert the anesthesia team and ensure cardiac monitoring (continuous 5-lead ECG, arterial line if available) is in place for induction and emergence.

Step 3: Continue Levothyroxine Through Surgery

Unless NPO rules require omitting all oral medications, instruct the patient to take their usual levothyroxine dose the morning of surgery with a small sip of water. Most anesthesiologists permit this. The American Thyroid Association 2014 guidelines on hypothyroidism management note that levothyroxine absorption is not significantly affected by the brief pre-operative fasting period, and that continuity of T4 dosing reduces the depth of post-operative hypothyroidism [9].

Step 4: Intraoperative Monitoring Priorities

Alert the anesthesia team to the patient's thyroid history. Key monitoring targets include:

• Heart rate below 90 bpm at induction
• Avoidance of ketamine as a primary induction agent if T3 was not fully held (ketamine stimulates catecholamine release)
• Blood pressure trending, especially at laryngoscopy
• Temperature monitoring throughout (thyroid hormone excess lowers the threshold for malignant hyperthermia-like syndromes, though true MH is a separate genetic condition)

Step 5: Post-operative Restart

Restart liothyronine 24 to 48 hours after surgery once the patient can swallow oral medications reliably and has no ongoing ileus or absorption concern. In patients who are NPO for more than 5 to 7 days post-operatively, intravenous levothyroxine (at 75 to 80% of the oral dose) maintains thyroid hormone levels. No intravenous formulation of liothyronine is currently FDA-approved for outpatient or routine perioperative use in hypothyroid patients, though IV T3 is used in myxedema coma protocols [10].

Special Populations and Edge Cases

Thyroid Cancer Patients on Suppressive Dosing

DTC survivors are often maintained on suppressive liothyronine to keep TSH below 0.5 mU/L (high-intermediate risk) or below 0.1 mU/L (high-risk) per ATA risk stratification [11]. These patients may be on 50 mcg or more of liothyronine daily, sometimes without any concomitant T4. Holding T3 for 7 to 10 days before surgery is still appropriate, but the oncologic implications must be discussed with the treating endocrinologist. A single 10-day window of TSH rise is unlikely to affect cancer outcomes but must be documented.

Patients with Atrial Fibrillation History

A history of atrial fibrillation (AF) is a strong argument for a full 10-day hold rather than a 7-day hold. T3 shortens the atrial refractory period and reduces the threshold for AF induction [12]. In these patients, a pre-operative thyroid function panel (free T3, free T4, TSH) obtained 24 to 48 hours before surgery provides confirmatory data that T3 has cleared.

Pregnancy and Obstetric Surgery

Pregnant patients requiring thyroid replacement need individualized management. Fetal T3 requirements increase across gestation. Holding liothyronine for 7 to 10 days in a pregnant patient is generally not appropriate without close endocrinologic co-management. This scenario is rare, but the hold recommendation applies primarily to non-pregnant adults undergoing elective procedures.

Pediatric Patients

Pediatric dosing of liothyronine is weight-based, and the same pharmacokinetic rationale for a 7-to-10-day hold applies. For children under 12, the anesthesia team should be involved in the hold decision given that pediatric hypothyroidism carries different neurodevelopmental stakes.

Thyroid Storm: A Low-Probability but High-Stakes Risk

Thyroid storm is the extreme end of thyroid hormone excess. It is defined clinically by the Burch-Wartofsky Point Scale and involves fever, tachycardia, altered mental status, and multi-organ dysfunction [13]. True thyroid storm from exogenous liothyronine is rare, but surgical stress is one of the recognized precipitants in patients with unrecognized hyperthyroidism or excessive thyroid hormone replacement.

Anesthesiologists at major academic centers have documented cases of intraoperative thyroid storm that were retrospectively attributed to unrecognized T3 excess in patients on combination thyroid therapy. The treatment is aggressive: beta-blockade with IV propranolol (1 mg every 10 to 15 minutes until heart rate is controlled), high-dose corticosteroids (hydrocortisone 300 mg IV daily), and antithyroid drugs if endogenous hyperthyroidism is contributing [14].

The HealthRX perioperative T3 risk framework categorizes patients into three tiers based on current liothyronine dose and cardiac history:

• Tier 1 (low risk): Liothyronine <25 mcg daily, no cardiac history, euthyroid on labs. Minimum 7-day hold.
• Tier 2 (moderate risk): Liothyronine 25 to 50 mcg daily, or history of AF or hypertension. 10-day hold plus pre-operative free T3 confirmation.
• Tier 3 (high risk): Liothyronine >50 mcg daily, active tachyarrhythmia, or DTC suppressive dosing. 10-day hold, endocrinology co-management, cardiology clearance, and continuous ECG monitoring at induction.

This framework has not been prospectively validated in a randomized trial. It is derived from pharmacokinetic modeling, ATA 2014 guidelines, and clinical consensus at HealthRX.

Laboratory Monitoring Around the Hold

Pre-Hold Baseline

Draw free T3, free T4, and TSH within 2 to 4 weeks before surgery if the patient has not had labs in the prior 3 months. This establishes whether the patient is already over-replaced or under-replaced before the hold begins.

Day-of-Surgery Labs

For Tier 2 and Tier 3 patients (see framework above), a point-of-care or rapid free T3 assay the morning of surgery confirms that T3 has cleared to reference range (<4.2 pg/mL in most laboratory reference intervals). This is not standard practice at every center, but it eliminates residual pharmacokinetic uncertainty.

Post-operative Monitoring

Check TSH and free T4 at 4 to 6 weeks after surgery and restart, particularly if there was any change in dose or if the patient had a prolonged post-operative course. The ATA 2014 hypothyroidism guideline recommends TSH monitoring every 6 to 12 months once stable, but a post-surgical disruption warrants an earlier check [9].

Communication Checklist for Prescribers

Patients on liothyronine prescribed through a telehealth provider face an added coordination challenge: their surgeon may be unaware of the T3 component of their thyroid regimen if the prescriber is not integrated with the surgical care team. The following communication steps reduce that gap:

1. Send a medication reconciliation note to the surgeon and anesthesia team at least 14 days before the procedure listing the exact liothyronine dose, hold start date, and planned restart date.
2. Instruct the patient to list liothyronine separately from levothyroxine on any medication forms, since many patients report both as "thyroid medication" without specifying which agent.
3. Confirm at the pre-operative nursing intake call that the last liothyronine dose was taken on the correct hold-start date.
4. Provide the post-operative restart prescription before surgery so the patient does not face a gap if the post-operative visit is delayed.

A 2020 analysis in JAMA Internal Medicine found that medication reconciliation errors at care transitions affect approximately 19% of surgical patients [15]. Thyroid medications are among the most frequently omitted from reconciliation lists because patients and non-endocrinology providers may underestimate their cardiovascular relevance.

Summary of Key Numbers

| Parameter | Liothyronine (T3) | Levothyroxine (T4) | |---|---|---| | Plasma half-life | ~1 day | ~7 days | | Receptor binding affinity (relative) | ~4x T4 | 1x | | Pre-surgery hold duration | 7 to 10 days | Morning-of omission only | | Time to steady state | 3 to 5 days | 4 to 6 weeks | | IV formulation available (US) | Yes (myxedema coma only) | Yes (routine periop use) | | Post-op restart | 24 to 48 hours post-op | Day of surgery or next morning |